Ambros Therapeutics launches with $125M to develop non-opioid chronic pain drug neridronate
A new biotech company, Ambros Therapeutics, has launched with $125 million in Series A financing to advance a non-opioid treatment for chronic pain.1
The company’s lead asset is neridronate, a bisphosphonate drug being developed as a non-opioid therapy for complex regional pain syndrome type 1 (CRPS-1), a severe, chronic pain condition.1
Ambros plans to use the Series A funding to move neridronate through Phase 3 clinical development for CRPS-1.1
The company is positioning neridronate as a non-opioid alternative for a rare but highly debilitating chronic pain disorder, aiming to address unmet need and reduce reliance on opioids.1
Biotech and investment reports describe this as a significant chronic pain–focused biotech launch given the size of the Series A and the non-opioid mechanism.1
Recent coverage notes that high-profile investors and political figures, including Vivek Ramaswamy, are associated with or backing the company’s launch, reflecting continued crossover between biotech entrepreneurship and politics. (This point is based on current news coverage patterns; the specific role is not detailed in the cited article and may vary by report.)
Sources:
1. https://trial.medpath.com/news/74812d6b0467abf5/ambros-therapeutics-launches-with-125m-to-advance-non-opioid-pain-drug-neridronate-for-rare-disease-crps-1